Liver Transplantation and Uveal Malignant Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01311466
Recruitment Status : Completed
First Posted : March 9, 2011
Last Update Posted : October 23, 2017
Information provided by (Responsible Party):
Svein Dueland, Oslo University Hospital

Brief Summary:
Patients with uveal malignant melanoma with liver metastases have median survival of less than 12 months. There is no established treatment showing increased overall survival. The study will determine if liver transplantation will result in long term survival in patients with liver metastases from uveal malignant melanoma.

Condition or disease Intervention/treatment
Uveal Malignant Melanoma Procedure: Liver transplantation

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Non-randomized Study to Assess the Benefit of Liver Transplantation in Patients With Liver Metastasis After Ocular Malignant Melanoma (Uveal Melanoma)
Study Start Date : January 2011
Primary Completion Date : October 2015
Study Completion Date : October 2015

Arm Intervention/treatment
Experimental: Liver transplantation
The liver transplantation will be performed as described by the standard protocol, Liver Transplantation Protocol (Version 2006) at the Oslo University Hospital
Procedure: Liver transplantation

Primary Outcome Measures :
  1. Over all survival [ Time Frame: 1 year ]
    Patient survival after livertransplantation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Uveal malignant melanoma
  • Liver metastases
  • ECOG 0-1

Exclusion Criteria:

  • Extra hepatic disease
  • Previous other malignancy
  • Previous organ transplantation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01311466

Oslo University Hospital
Oslo, Norway, N0310
Sponsors and Collaborators
Oslo University Hospital
Principal Investigator: Svein Dueland, MD, PhD Oslo University Hospital, Radium hospitalet

Responsible Party: Svein Dueland, MD PhD, Oslo University Hospital Identifier: NCT01311466     History of Changes
Other Study ID Numbers: S-06408
First Posted: March 9, 2011    Key Record Dates
Last Update Posted: October 23, 2017
Last Verified: October 2017

Keywords provided by Svein Dueland, Oslo University Hospital:
Liver transplantation
Overall survival

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Liver Extracts